News Releases

April 17, 2019 at 5:05 PM EDT

Summary Toggle CryoLife Announces Release Date and Teleconference Call Details for 2019 First Quarter Financial Results

ATLANTA , April 17, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 first quarter financial results will be released on Tuesday, April 30, 2019 after the market closes. On that day, the Company
April 3, 2019 at 8:30 AM EDT

Summary Toggle CryoLife to Present at 18th Annual Needham Healthcare Conference

ATLANTA , April 3, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 18 th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at the Westin Grand Central
March 5, 2019 at 5:00 PM EST

Summary Toggle CryoLife to Present at Cowen and Company 39th Annual Health Care Conference

ATLANTA , March 5, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Cowen and Company 39 th Annual Health Care Conference on Monday, March 11, 2019 at The Boston
February 13, 2019 at 7:30 PM EST

Summary Toggle CryoLife Reports Fourth Quarter and Full Year 2018 Financial Results

ATLANTA , Feb. 13, 2019 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Total revenues were $67.8 million in the fourth quarter of 2018, reflecting year over year growth of 28% and an 8% increase on a non-GAAP constant currency basis compared to the fourth quarter of 2017 On-X ®
February 1, 2019 at 5:00 PM EST

Summary Toggle CryoLife Announces Release Date and Teleconference Call Details for 2018 Fourth Quarter and Year-end Financial Results

ATLANTA , Feb. 1, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2018 fourth quarter and year-end financial results will be released on Wednesday, February 13, 2019 after the market closes.
October 31, 2018 at 5:04 PM EDT

Summary Toggle CryoLife Reports Third Quarter 2018 Results

ATLANTA , Oct. 31, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the third quarter ended September 30, 2018 . Third Quarter and Recent Business Highlights: Total revenues
October 15, 2018 at 5:00 PM EDT

Summary Toggle CryoLife Reports Preliminary Financial Results for Third Quarter 2018 in Anticipation of Discussions with Senior Lenders Regarding Repricing Senior Credit Facility

Announces Release Date and Teleconference Call Details for 2018 Third Quarter Financial Results ATLANTA , Oct. 15, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, in anticipation of discussions with its senior lenders
September 18, 2018 at 5:00 PM EDT

Summary Toggle CryoLife to Present at Deutsche Bank 26th Annual Leveraged Finance Conference

ATLANTA , Sept. 18, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Deutsche Bank 26 th Annual Leveraged Finance Conference on Tuesday, October 2, 2018 at The
August 6, 2018 at 5:30 PM EDT

Summary Toggle CryoLife Reports Second Quarter 2018 Results

ATLANTA , Aug. 6, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the second quarter ended June 30 , 2018. Second Quarter and Recent Business Highlights: Total revenues increased
July 26, 2018 at 8:30 AM EDT

Summary Toggle CryoLife to Present at 38th Annual Canaccord Genuity Growth Conference

ATLANTA , July 26, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 38 th Annual Canaccord Genuity Growth Conference on Thursday, August 9, 2018 at the